Robinson Byron's most recent trade in Janux Therapeutics Inc was a trade of 98,000 Stock option (right to buy) done . Disclosure was reported to the exchange on Jan. 2, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Janux Therapeutics Inc | Byron Robinson | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 98,000 | 98,000 | - | - | Stock option (right to buy) | |
Janux Therapeutics Inc | Byron Robinson | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 28,000 | 28,000 | - | 0 | Common Stock | |
Janux Therapeutics Inc | Robinson Byron | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 151,500 | 151,500 | - | - | Stock Option (right to buy) | |
Janux Therapeutics Inc | Byron Robinson | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
Janux Therapeutics Inc | Byron Robinson | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 230,000 | 230,000 | - | - | Stock Option (right to buy) |